A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis

Trial Profile

A Long-term, Open-label Follow-up Study Of Tofacitinib (Cp-690,550) For Treatment Of Rheumatoid Arthritis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms ORAL-Sequel
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Dec 2017 This trial has been completed in Germany (End Date: 2017-10-26).
    • 08 Nov 2017 Results of pooled data from two trial (NCT02147587 and NCT00413699) assessing evaluate the long-term effectiveness of LZV in patients with RA, via the incidence of HZ after treatment with tofacitinib for up to 27 months, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 08 Nov 2017 Pooled results of two open-label studies (NCT00413699 and NCT00661661; n=4967) assessing long-term safety and efficacy of Tofacitinib over 9 years, presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top